Neurones Balance Sheet Health

Financial Health criteria checks 5/6

Neurones has a total shareholder equity of €399.0M and total debt of €11.2M, which brings its debt-to-equity ratio to 2.8%. Its total assets and total liabilities are €679.4M and €280.5M respectively. Neurones's EBIT is €73.6M making its interest coverage ratio -10.7. It has cash and short-term investments of €268.1M.

Key information

2.8%

Debt to equity ratio

€11.21m

Debt

Interest coverage ratio-10.7x
Cash€268.12m
Equity€398.95m
Total liabilities€280.50m
Total assets€679.45m

Recent financial health updates

No updates

Recent updates

What Neurones S.A.'s (EPA:NRO) P/E Is Not Telling You

Jul 27
What Neurones S.A.'s (EPA:NRO) P/E Is Not Telling You

Returns On Capital At Neurones (EPA:NRO) Have Hit The Brakes

Apr 26
Returns On Capital At Neurones (EPA:NRO) Have Hit The Brakes

Slowing Rates Of Return At Neurones (EPA:NRO) Leave Little Room For Excitement

Dec 01
Slowing Rates Of Return At Neurones (EPA:NRO) Leave Little Room For Excitement

If EPS Growth Is Important To You, Neurones (EPA:NRO) Presents An Opportunity

May 18
If EPS Growth Is Important To You, Neurones (EPA:NRO) Presents An Opportunity

Neurones' (EPA:NRO) Returns Have Hit A Wall

Feb 10
Neurones' (EPA:NRO) Returns Have Hit A Wall

Slowing Rates Of Return At Neurones (EPA:NRO) Leave Little Room For Excitement

Oct 26
Slowing Rates Of Return At Neurones (EPA:NRO) Leave Little Room For Excitement

Does Neurones (EPA:NRO) Deserve A Spot On Your Watchlist?

Sep 22
Does Neurones (EPA:NRO) Deserve A Spot On Your Watchlist?

Neurones (EPA:NRO) Will Pay A Smaller Dividend Than Last Year

Apr 28
Neurones (EPA:NRO) Will Pay A Smaller Dividend Than Last Year

Should You Be Adding Neurones (EPA:NRO) To Your Watchlist Today?

Jan 25
Should You Be Adding Neurones (EPA:NRO) To Your Watchlist Today?

Returns At Neurones (EPA:NRO) Appear To Be Weighed Down

Jan 06
Returns At Neurones (EPA:NRO) Appear To Be Weighed Down

Returns On Capital At Neurones (EPA:NRO) Paint A Concerning Picture

Jul 20
Returns On Capital At Neurones (EPA:NRO) Paint A Concerning Picture

Is Neurones S.A. (EPA:NRO) Trading At A 25% Discount?

May 06
Is Neurones S.A. (EPA:NRO) Trading At A 25% Discount?

Some Investors May Be Worried About Neurones' (EPA:NRO) Returns On Capital

Mar 24
Some Investors May Be Worried About Neurones' (EPA:NRO) Returns On Capital

Neurones S.A.'s (EPA:NRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Mar 09
Neurones S.A.'s (EPA:NRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

The Neurones (EPA:NRO) Share Price Has Gained 54% And Shareholders Are Hoping For More

Feb 16
The Neurones (EPA:NRO) Share Price Has Gained 54% And Shareholders Are Hoping For More

Here's Why Neurones's (EPA:NRO) Statutory Earnings Are Arguably Too Conservative

Jan 25
Here's Why Neurones's (EPA:NRO) Statutory Earnings Are Arguably Too Conservative

What Percentage Of Neurones S.A. (EPA:NRO) Shares Do Insiders Own?

Jan 11
What Percentage Of Neurones S.A. (EPA:NRO) Shares Do Insiders Own?

Should Neurones S.A. (EPA:NRO) Be Part Of Your Dividend Portfolio?

Dec 28
Should Neurones S.A. (EPA:NRO) Be Part Of Your Dividend Portfolio?

Are Neurones S.A. (EPA:NRO) Investors Paying Above The Intrinsic Value?

Dec 15
Are Neurones S.A. (EPA:NRO) Investors Paying Above The Intrinsic Value?

What We Learned About Neurones' (EPA:NRO) CEO Pay

Dec 02
What We Learned About Neurones' (EPA:NRO) CEO Pay

Investors Who Bought Neurones (EPA:NRO) Shares Five Years Ago Are Now Up 39%

Nov 17
Investors Who Bought Neurones (EPA:NRO) Shares Five Years Ago Are Now Up 39%

Neurones (EPA:NRO) Is Growing Earnings But Are They A Good Guide?

Jun 30
Neurones (EPA:NRO) Is Growing Earnings But Are They A Good Guide?

Financial Position Analysis

Short Term Liabilities: NRO's short term assets (€546.3M) exceed its short term liabilities (€243.4M).

Long Term Liabilities: NRO's short term assets (€546.3M) exceed its long term liabilities (€37.1M).


Debt to Equity History and Analysis

Debt Level: NRO has more cash than its total debt.

Reducing Debt: NRO's debt to equity ratio has increased from 0% to 2.8% over the past 5 years.

Debt Coverage: NRO's debt is well covered by operating cash flow (554.5%).

Interest Coverage: NRO earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 11:30
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Neurones S.A. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gilbert FerrandArkeon Finance
Alexandre PlaudCIC Market Solutions (ESN)
Richard-Maxime BeaudouxNatixis S.A.